Increased systemic exposure w/ strong CYP3A4 inhibitors (eg, ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, nefazodone). Decreased systemic exposure w/ CYP3A4 inducers (eg, rifampicin, rifabutin, carbamazepine, phenytoin, St. John's wort); PPIs (eg, esomeprazole). Altered exposure &/or distribution w/ P-gp or BCRP inhibitors (eg, ketoconazole, itraconazole, quinidine, verapamil, cyclosporine, erythromycin) & inducers (eg, rifampicin, St. John's wort). Decreased solubility & absorption w/ substances that increase gastric pH. Increased AUC of oral midazolam; SN-38 (active metabolite of irinotecan); oral digoxin. Avoid concomitant use w/ substrates of CYP3A4 (eg, cisapride, pimozide, quinidine) & CYP2C8 (eg, repaglinide) w/ narrow therapeutic windows. Increased exposure of IV paclitaxel. Increased occurrence of docetaxel-induced neutropenia when co-administered w/ IV docetaxel. May affect pharmacokinetics of substrates of BCRP (eg, topotecan) & OATP1B1 (eg, rosuvastatin). Increased bioavailability w/ fatty meals; grapefruit juice.